IP Library Granted Patent US 7,771,980
Granted Patent B2
US 7,771,980 · App. 12/243,437 · Granted Aug 10, 2010

Production of poxviruses with adherent or non adherent avian cell lines

Assignee: Vivalis
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,771,980
App. No.
12/243,437
Granted
Aug 10, 2010
Kind
B2
Abstract

The present invention relates to a method for replicating poxviruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced viral particles are released in said medium.

Claims (13)

1. Avian embryonic derived stem cells which proliferate in suspension in a medium free of serum (serum-free medium) which have been inoculated with viral particles of vaccinia virus and which replicate said viral particles of vaccinia virus.

2. The avian embryonic derived stem cells of claim 1 , wherein said avian embryonic derived stem cells are chicken or duck embryonic derived stem cells.

3. The avian embryonic derived stem cells of claim 1 , wherein said vaccinia virus is the native Modified Vaccinia virus Ankara (MVA) or a recombinant thereof.

4. The avian embryonic derived stem cells of claim 1 , wherein said avian embryonic derived stem cells have at least one of the following characteristics:

a high nucleo-cytoplasmic ratio,

an endogenous alkaline phosphatase activity,

an endogenous telomerase activity,

a reactivity with specific antibodies selected from the group of antibodies SSEA-1 (TEC01), SSEA-3, and EMA-1.

5. The avian embryonic derived stem cells of claim 1 , wherein said avian embryonic derived stem cells have the following characteristics:

a high nucleo-cytoplasmic ratio, and

an endogenous alkaline phosphatase activity, and

an endogenous telomerase activity, and

a reactivity with specific antibodies selected from the group of antibodies SSEA-1 (TEC01), SSEA-3, and EMA-1.

Assignments (1)
CHANGE OF NAME Recorded Nov 20, 2014
From: VIVALIS
To: VALNEVA
Reel/Frame 034219/0982 →
Priority Claims (2)
EP 03291813 · Jul 22, 2003 · regional
FR 03 14389 · Dec 9, 2003 · national
Continuity (2)
Division 1056528100
Related Publication 20090239286A1 · Sep 24, 2009